Skip to search formSkip to main contentSkip to account menu

Seliciclib

An orally available small molecule and cyclin-dependent kinase (CDK) inhibitor with potential apoptotic and antineoplastic activity. CDKs, serine… 
National Institutes of Health

Related topics

Related topics

9 relations
CYC 202Cyclin-Dependent KinasesGene Expression RegulationNCIt Antineoplastic Agent Terminology

Broader (1)

roscovitine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The cyclin-dependent kinase inhibitor p57Kip2 is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
Background:Carboplatin remains a first-line agent in the management of epithelial ovarian cancer (EOC). Unfortunately, platinum… 
2011
2011
Raman micro-spectroscopic analysis of cultured HCT116 colon cancer cells in the presence of roscovitine.
2011
2011
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases
Small molecular inhibitors of Cyclin dependent kinases (Cdks) are currently being developed as anticancer therapeutics due to… 
2011
2011
Transcriptional modulation of apoptosis regulators by roscovitine and related compounds
Chemical inhibitors of cyclin-dependent kinase (CDK), like roscovitine, are promising drugs in the context of new cancer… 
2011
2011
Treatment with a cyclin‐dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis
Aim:  The cyclin‐dependent kinase inhibitor, seliciclib (R‐roscovitine, CYC202), has anti‐proliferative activity through its… 
Highly Cited
2009
Highly Cited
2009
Seliciclib (CYC202, R‐roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model
We sought to determine whether seliciclib (CYC202, R‐roscovitine) could increase the antitumor effects of doxorubicin, with no… 
2008
2008
Metabolism of the Trisubstituted Purine Cyclin-Dependent Kinase Inhibitor Seliciclib (R-Roscovitine) in Vitro and in Vivo
Seliciclib (R-roscovitine, CYC202) is a small molecule inhibitor of cyclin-dependent kinases currently in phase II clinical… 
2007
2007
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas
Despite recent improvements in treatment, a significant fraction of patients with diffuse large B-cell lymphoma (DLBCL) still… 
2005
2005
Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC).
2060 Background: Seliciclib (CYC202 or R-roscovitine) is a potent inhibitor of cyclin dependent kinases including CDK2/cyclin E… 
Highly Cited
2005
Highly Cited
2005
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
R-roscovitine (seliciclib, CYC202) is a cyclin-dependent kinase inhibitor currently in phase II clinical trials in patients with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)